Opinion|Videos|December 1, 2025
Other Key Data in Gastric/GEJ Cancer Presented at ESMO 2025
Author(s)Yelena Y. Janjigian, MD, Zev A. Wainberg, MD
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss other key gastric cancer data presented at the 2025 ESMO Congress.
Advertisement
Episodes in this series
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, highlight additional noteworthy gastric and GEJ cancer studies showcased at the 2025 ESMO Congress, including larger trials with potential practice-changing impact. They discuss emerging agents and novel combinations that may introduce new mechanisms of action or refine treatment sequencing, along with promising early-phase data that warrant continued attention as future therapeutic contenders. In particular, they delve into findings from the MATTERHORN trial that could bring perioperative immunotherapy to gastric/GEJ cancer management.
Advertisement
Related to this article
The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
Anktiva plus BCG improved efficacy vs BCG alone in cohort A of QUILT-2.005 in BCG-naive NMIBC.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
SER-155 showed early promise in reducing bloodstream infections in patients undergoing donor stem cell transplants for blood cancers.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
During a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
Trine Jakobi Nøttrup, MD, PhD, discusses data for the hTERT-directed vaccine UV1 in BRCA wild-type recurrent ovarian cancer/
Advertisement
Advertisement
Trending on OncLive
1
Cesalatamig Monotherapy Shows Dose-Dependent Activity in PD-(L)1 Inhibitor–Experienced NSCLC
2
Dr Moser on Outcomes for WTX-124 ± Pembrolizumab in Advanced Immune-Sensitive Solid Tumors
3
Dr Banks on the Feasibility of Lifileucel in Select Metastatic Sarcomas
4
BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R Myeloma
5